Immunologic Effects and Tolerability Profile of In-Season Initiation of a Standardized-Quality Grass Allergy Immunotherapy Tablet: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial in Adults with Grass Pollen–Induced Rhinoconjunctivitis

Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study

“…The mean age of the patients and the number of diagnostic tests to identify grass pollen allergy were, however, higher in patients treated by allergists. Nevertheless, the results of this study confirm the results of a previous RDBPC clinical trial [18] and a non-interventional study [19] that have demonstrated intra-seasonal initiation of treatment with the SQ Ò grass SLIT tablet to be feasible and well-tolerated.…”

“…The feasibility and good tolerability of an intra-seasonal initiation of AIT with the SQ Ò grass SLIT tablet has been shown in a previous RDBPC trial and was confirmed by a large noninterventional study in real life [18,19].…”

“…The safety, tolerability, data on adherence, effectiveness and health-related quality of life have been investigated in several non-interventional, observational studies with the SQ Ò grass SLIT tablet in real-life application by allergists in Germany, including a study on intra-seasonal initiation of treatment with more than 600 patients [19][20][21][22] that confirmed results from a previous Randomized double-blind placebo-control (RDBPC) trial [18]. A cohort study, including all German National Health beneficiaries insured by the German health insurance provider AOK PLUS (Saxony) from 2005 to 2011, revealed a proportion of 36.2% of adult patients with allergic rhinitis treated exclusively by general practitioners, and a proportion of 21.2% of children [23].…”

“…The standardised sublingual grass allergy immunotherapy tablet (SQ Ò grass SLIT tablet) has been developed for sublingual application in patients with grass pollen-induced rhinoconjunctivitis, and has been investigated in more than 5700 patients in controlled clinical trials in Europe and North America [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. It has been approved Europe-wide and was launched in Germany in November 2006.…”

Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review

“…The frequency of discontinuation with coseasonal initiation was 7% or less in the remaining SLIT studies (see Table E4 in this article's Online Repository at www.jaci-inpractice.org). [17][18][19][20][26][27][28][29][30][31] This discontinuation rate is similar (ranges from 1% to 6%) to published data for treatment initiation outside of the season. 32,33 Systemic allergic reactions in SLIT coseasonal initiation studies…”